Noribogaine Therapy for Relief of Opioid withdrawal, Phase 1B
A Phase 1B, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Noribogaine in Opioid Dependent Participants Seeking to Discontinue Methadone Opioid Substitution Treatment (OST)
DemeRx Inc
27 participants
Oct 14, 2013
Interventional
Conditions
Summary
This is a research study to evaluate the safety, tolerability and effects of noribogaine, an atypical opioid. We will also be looking at its effects on opioid withdrawal symptoms in opioid dependent people who are maintained on stable doses of methadone and who want to stop taking methadone.
Eligibility
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administration of a single oral dose of noribogaine. It is planned that the first dose cohort will receive 60mg, the second cohort 120mg and the third cohort 180mg. Noribogaine will be administered under supervision at the study site.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001064796